Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1

• Published in: The Journal of clinical investigation Vol. 131; no. 14
• Main Authors: Meisel, Christian, Akbil, Bengisu, Meyer, Tim, Lankes, Erwin, Corman, Victor M., Staudacher, Olga, Unterwalder, Nadine, Kölsch, Uwe, Drosten, Christian, Mall, Marcus A., Kallinich, Tilmann, Schnabel, Dirk, Goffinet, Christine, von Bernuth, Horst
• Format: Journal Article
• Language: English
• Published: United States American Society for Clinical Investigation 15.07.2021
• Subjects: Adolescent; Adult; AIRE Protein; Antibodies, Neutralizing - blood; Antibodies, Neutralizing - immunology; Autoantibodies; Autoantibodies - blood; Autoantibodies - immunology; Autoimmune diseases; Concise Communication; COVID-19 - complications; COVID-19 - immunology; Development and progression; Endocrine gland diseases; Female; Genetic aspects; Health aspects; Humans; In Vitro Techniques; Interferon; Interferon Type I - antagonists & inhibitors; Interferon Type I - immunology; Interferon-alpha - antagonists & inhibitors; Interferon-alpha - immunology; Male; Polyendocrinopathies, Autoimmune - complications; Polyendocrinopathies, Autoimmune - genetics; Polyendocrinopathies, Autoimmune - immunology; SARS-CoV-2 - immunology; SARS-CoV-2 - physiology; Severity of Illness Index; Transcription Factors - genetics; Virus Replication - immunology; Young Adult; Germany; COVID-19; Innate immunity; Immunology

Autoantibodies against IFN-α and IFN-ω (type I IFNs) were recently reported as causative for severe COVID-19 in the general population. Autoantibodies against IFN-α and IFN-ω are present in almost all patients with autoimmune polyendocrine syndrome type 1 (APS-1) caused by biallelic deleterious or h...